The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Contribution of remnant cholesterol to cardiovascular risk
Open accessAbstract
Background: Remnant cholesterol in triglyceride‐rich lipoproteins is associated observationally and genetic, causally with increased risk of atherosclerotic cardiovascular disease in healthy individuals. Objectives: We tested the hypothesis that an unmet medical need exists in individuals with high nonfasting remnant cholesterol and prior atherosclerotic cardiovascular disease. Methods: From amongst 109 574 individuals in a prospective cohort study of the Danish general population, we included 2973 individuals aged 20–80 with baseline diagnoses of myocardial infarction/ischaemic stroke ascertained from national Danish health registries. Results: The recurrent major cardiovascular event (MACE) incidence rates per 1000 person‐years were 39 (95% confidence interval: 30–50) for individuals with remnant cholesterol levels ≥ 1.5 mmol L−1 (≥58 mg dL−1), 31 (26–37) for 1–1.49 mmol L−1 (39–57 mg dL−1), 27 (24–31) for 0.5–0.99 mmol L−1 (19‐38 mg dL−1) and 23 (19–27) for individuals with remnant cholesterol < 0.5 mmol L−1 (<19 mg dL−1). Compared to individuals with remnant cholesterol < 0.5 mmol L−1 (<19 mg dL−1), the subhazard ratio for recurrent MACE was 1.23 (95% CI: 0.98–1.55) for individuals with remnant cholesterol levels of 0.5–0.99 mmol L−1 (19–38 mg dL−1), 1.48 (1.14–1.92) for 1–1.49 mmol L−1 (39–57 mg dL−1) and 1.79 (1.28–2.49) for ≥ 1.5 mmol L−1 (≥58 mg dL−1). The recurrent MACE incidence rates per 1000 person‐years for individuals with remnant cholesterol levels < 0.5 mmol L−1 (<19 mg dL−1) and ≥ 1.5 mmol L−1 (≥58 mg dL−1) were 10 (6.6–15) and 31 (21–47) for those below age 65 and correspondingly 25 (21–30) and 43 (32–59) for those with LDL cholesterol levels < 3 mmol L−1 (<116 mg dL−1), respectively. For a 20% recurrent MACE risk reduction in secondary prevention, an estimated remnant cholesterol lowering of 0.83 mmol L−1 (32 mg dL−1) would be needed. Conclusions: In individuals with a diagnosis of myocardial infarction/ischaemic stroke, a lower remnant cholesterol of 0.8 mmol L−1 (32 mg dL−1) was estimated to reduce recurrent MACE by 20% in secondary prevention. Our data indicate an unmet medical need for secondary prevention in individuals with high nonfasting remnant cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Self-citationNordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Self-citationRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Self-citationEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citation
Cited by
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease
Castañer, O., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, Á., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Estruch, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.008 · Cited by 540
“83 mmol/l) was estimated to reduce recurrent MACEs by 20% in secondary prevention (43).”
BackgroundTardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab820 · Cited by 210
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
Rosenson, R. S., Gaudet, D., Hegele, R. A., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., San Martin, J., Zhou, R., Muhsin, M., Chang, T., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404147 · Cited by 249
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Ballantyne, C. M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R. S., Chang, T., Melquist, S., Zhou, R., Mushin, M., Leeper, N. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404143 · Cited by 210
Metadata
- Authors
- Langsted, A., Madsen, C. M., & Nordestgaard, B. G.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2020-04-07
- Volume
- 288
- Issue
- 1
- Pages
- 116-127
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W3012506567
- Cited by
- 189
- References
- 26
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contribution of remnant cholesterol to cardiovascular risk. https://app.cochat.ai/papers/10.1111/joim.13059
- The paper
- Langsted, A., Madsen, C. M., & Nordestgaard, B. G. (2020). Contribution of remnant cholesterol to cardiovascular risk. Journal of Internal Medicine. https://doi.org/10.1111/joim.13059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.